These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 18829454)
1. Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone. Sharlow ER; Giridhar KV; LaValle CR; Chen J; Leimgruber S; Barrett R; Bravo-Altamirano K; Wipf P; Lazo JS; Wang QJ J Biol Chem; 2008 Nov; 283(48):33516-26. PubMed ID: 18829454 [TBL] [Abstract][Full Text] [Related]
2. Discovery of diverse small molecule chemotypes with cell-based PKD1 inhibitory activity. Sharlow ER; Mustata Wilson G; Close D; Leimgruber S; Tandon M; Reed RB; Shun TY; Wang QJ; Wipf P; Lazo JS PLoS One; 2011; 6(10):e25134. PubMed ID: 21998636 [TBL] [Abstract][Full Text] [Related]
3. TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Hikichi Y; Honda K; Hikami K; Miyashita H; Kaieda I; Murai S; Uchiyama N; Hasegawa M; Kawamoto T; Sato T; Ichikawa T; Cao S; Nie Z; Zhang L; Yang J; Kuida K; Kupperman E Mol Cancer Ther; 2012 Mar; 11(3):700-9. PubMed ID: 22188812 [TBL] [Abstract][Full Text] [Related]
4. CID755673 enhances mitogenic signaling by phorbol esters, bombesin and EGF through a protein kinase D-independent pathway. Torres-Marquez E; Sinnett-Smith J; Guha S; Kui R; Waldron RT; Rey O; Rozengurt E Biochem Biophys Res Commun; 2010 Jan; 391(1):63-8. PubMed ID: 19896460 [TBL] [Abstract][Full Text] [Related]
5. Identification of novel, potent and selective inhibitors of Polo-like kinase 1. Chen S; Bartkovitz D; Cai J; Chen Y; Chen Z; Chu XJ; Le K; Le NT; Luk KC; Mischke S; Naderi-Oboodi G; Boylan JF; Nevins T; Qing W; Chen Y; Wovkulich PM Bioorg Med Chem Lett; 2012 Jan; 22(2):1247-50. PubMed ID: 22172702 [TBL] [Abstract][Full Text] [Related]
6. The PKD inhibitor CID755673 enhances cardiac function in diabetic db/db mice. Venardos K; De Jong KA; Elkamie M; Connor T; McGee SL PLoS One; 2015; 10(3):e0120934. PubMed ID: 25798941 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of protein kinase D by CID755673 promotes maintenance of the pluripotency of embryonic stem cells. Zhu Z; Zhang Y; Wang X; Wang X; Ye SD Development; 2020 Aug; 147(16):. PubMed ID: 32747433 [TBL] [Abstract][Full Text] [Related]
8. New pyrazolopyrimidine inhibitors of protein kinase d as potent anticancer agents for prostate cancer cells. Tandon M; Johnson J; Li Z; Xu S; Wipf P; Wang QJ PLoS One; 2013; 8(9):e75601. PubMed ID: 24086585 [TBL] [Abstract][Full Text] [Related]
9. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1. Shan HM; Shi Y; Quan J ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850 [TBL] [Abstract][Full Text] [Related]
10. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain. Chen Y; Zhang J; Li D; Jiang J; Wang Y; Si S Oncotarget; 2017 Jan; 8(1):1234-1246. PubMed ID: 27902479 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1 (Plk1) inhibitors. Chen DX; Huang J; Liu M; Xu YG; Jiang C Arch Pharm (Weinheim); 2015 Jan; 348(1):2-9. PubMed ID: 25430493 [TBL] [Abstract][Full Text] [Related]
12. Discovery of Novel Polo-Like Kinase 1 Polo-Box Domain Inhibitors to Induce Mitotic Arrest in Tumor Cells. Qin T; Chen F; Zhuo X; Guo X; Yun T; Liu Y; Zhang C; Lai L J Med Chem; 2016 Aug; 59(15):7089-96. PubMed ID: 27425654 [TBL] [Abstract][Full Text] [Related]
13. Discovery of TAK-960: an orally available small molecule inhibitor of polo-like kinase 1 (PLK1). Nie Z; Feher V; Natala S; McBride C; Kiryanov A; Jones B; Lam B; Liu Y; Kaldor S; Stafford J; Hikami K; Uchiyama N; Kawamoto T; Hikichi Y; Matsumoto S; Amano N; Zhang L; Hosfield D; Skene R; Zou H; Cao X; Ichikawa T Bioorg Med Chem Lett; 2013 Jun; 23(12):3662-6. PubMed ID: 23664874 [TBL] [Abstract][Full Text] [Related]
14. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain. Shin SB; Woo SU; Yim H J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351 [TBL] [Abstract][Full Text] [Related]
15. Developments of polo-like kinase 1 (Plk1) inhibitors as anti-cancer agents. Li S; Zhang Y; Xu W Mini Rev Med Chem; 2013 Dec; 13(14):2014-25. PubMed ID: 24160708 [TBL] [Abstract][Full Text] [Related]
16. Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold. Lv X; Yang X; Zhan MM; Cao P; Zheng S; Peng R; Han J; Xie Z; Tu Z; Liao C Eur J Med Chem; 2019 Dec; 184():111769. PubMed ID: 31629162 [TBL] [Abstract][Full Text] [Related]
17. Evidence for a role of MRCK in mediating HeLa cell elongation induced by the C1 domain ligand HMI-1a3. Talman V; Gateva G; Ahti M; Ekokoski E; Lappalainen P; Tuominen RK Eur J Pharm Sci; 2014 May; 55():46-57. PubMed ID: 24486483 [TBL] [Abstract][Full Text] [Related]
18. Identification of acylthiourea derivatives as potent Plk1 PBD inhibitors. Yun T; Qin T; Liu Y; Lai L Eur J Med Chem; 2016 Nov; 124():229-236. PubMed ID: 27592392 [TBL] [Abstract][Full Text] [Related]
19. Development and implementation of a miniaturized high-throughput time-resolved fluorescence energy transfer assay to identify small molecule inhibitors of polo-like kinase 1. Sharlow ER; Leimgruber S; Shun TY; Lazo JS Assay Drug Dev Technol; 2007 Dec; 5(6):723-35. PubMed ID: 18181689 [TBL] [Abstract][Full Text] [Related]
20. Discovery of Non-ATP-Competitive Inhibitors of Polo-like Kinase 1. Yun T; Qin T; Liu Y; Lai L ChemMedChem; 2016 Apr; 11(7):713-7. PubMed ID: 27061239 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]